ENTX (Entera Bio) Debt-to-Asset : 0.03 (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Entera Bio Debt-to-Asset?

Entera Bio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.17 Mil. Entera Bio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.10 Mil. Entera Bio's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was $9.39 Mil. Entera Bio's debt to asset for the quarter that ended in Dec. 2024 was 0.03.

Entera Bio Debt-to-Asset Historical Data

The historical data trend for Entera Bio's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entera Bio Debt-to-Asset Chart

Entera Bio Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

Get a 7-Day Free Trial

0.04

0.01

0.03

Entera Bio Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial															0.03	0.04	0.03	0.04	0.03

Competitive Comparison of Entera Bio's Debt-to-Asset

For the Biotechnology subindustry, Entera Bio's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Entera Bio's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entera Bio's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Entera Bio's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Entera Bio Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Entera Bio's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.17	+	0.102)	/	9.39
	=	0.03

Entera Bio's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.17	+	0.102)	/	9.39
	=	0.03

Entera Bio (NAS:ENTX) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Entera Bio Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Entera Bio's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Entera Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entera Bio Ltd (NAS:ENTX) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

5DT:Germany

Address

Minrav Building - Fifth Floor, Kiryat Hadassah, Jerusalem, ISR, 9112002

Website

https://www.enterabio.com

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

Executives

Haya Taitel	director	KIRYAT HADASSAH, MINRAV BUILDING, 5TH FLOOR, JERUSALEM L3 9112002
Miranda Jayne Toledano	director	C/O COMPASS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 601, BOSTON MA 02135
Gerald M Lieberman	director	C/O ALLIANCE CAPITAL, 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105
Sean Ellis	director	KIRYAT HADASSAH, MINRAV BUILDING, FIFTH FLOOR, JERUSALEM L3 9112002
Dana Yaacov-garbeli	officer: Israel CFO	KIRYAT HADASSAH, MINRAV BUILDING, FIFTH FLOOR, JERUSALEM L3 9112002
Phillip Schwartz	director, officer: President of R&D	C/O ENTERA BIO LTD., KIRYAT HADASSAH, MINRAV BUILDING, 5TH FL, JERUSALEM L3 9112002
Ramesh Ratan	officer: U.S.based CFO	KIRYAT HADASSAH, MINRAV BUILDING, FIFTH FLOOR, JERUSALEM L3 9112002
Ron Mayron	director	22A ORANIM ST, HOD HASHARON L3 4526333
Spiros Jamas	director, officer: Chief Executive Officer
Gerald M Ostrov	director	41 WATERVIEW, LONG BRANCH NJ 07740
Yonatan Malca	director	KIRYAT HADASSAH, MINRAV BUILDING, FIFTH FLOOR, JERUSALEM L3 9112002
Roger Garceau	director	550 HILLS DRIVE, BEDMINSTER NJ 07921
Hillel Galitzer	officer: Chief Operating Officer	KIRYAT HADASSAH, MINRAV BUILDING, FIFTH FLOOR, JERUSALEM L3 9112002
Santora Arthur C Ii	officer: Chief Medical Officer	KIRYAT HADASSAH, MINRAV BUILDING, FIFTH FLOOR, JERUSALEM L3 9112002